William G. Wierda, MD, PhD, on Lisocabtagene Maraleucel in Relapsed/Refractory CLL: TRANSCEND CLL 004
2025 ASCO Annual Meeting
William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses two abstracts on lisocabtagene maraleucel (liso-cel) in relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). In Abstract 7037, liso-cel with ibrutinib demonstrated better efficacy and safety compared with liso-cel monotherapy, with statistically significant differences for complete response rate and overall response rate. In Abstract 7039, patients with R/R CLL/SLL who had received two or more prior lines of therapy had improved response, delayed progression, and prolonged survival with liso-cel compared with a real-world cohort treated with standard-of-care therapy.
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Confirmed — I have only corrected spelling errors and left all wording unchanged. Here is the revised transcript as one continuous paragraph:
I'd like to summarize 2 posters that I'm presenting at ASCO this year. Poster 7039 and 7037—7039 is a poster that presents an updated analysis of liso-cel monotherapy and its analysis of a comparison of a standard of care cohort of patients that was collected through multiple databases. Those were all previously treated patients and the concept is to compare outcomes for liso-cel and patients with similar characteristics as those treated on the TRANSCEND 004 trial who received standard of care treatment and their outcomes versus the outcomes for patients treated with liso-cel monotherapy on the TRANSCEND CLL 004 trial. That analysis showed improved outcomes for patients who were treated with liso-cel. These were all previously treated patients, all had had prior exposure to a BTK inhibitor and the BCL2 inhibitor-based therapy. And the progression-free survival was significantly better at a median of 14 months with liso-cel compared to about four months with a standard of care option. And the overall survival was improved with a median overall survival for liso-cel of 33 months and the median overall survival for standard of care of about 14 months. And so this analysis and comparison in the absence of a randomized trial gives us some insight into the improved outcome seen with liso-cel monotherapy compared to a standard of care option. The other abstract is 7037. This was an analysis with a propensity score comparing outcomes for patients treated with liso-cel monotherapy, the CD19 CAR T-cell therapy, versus liso-cel with ibrutinib. Now there is data, historic data, that demonstrated an improved product could be generated if the T cells were harvested for production while patients were on ibrutinib. In addition, for patients treated with liso-cel or with a CD19 CAR T-cell therapy while on ibrutinib, there was an indication of improved progression-free survival and overall outcomes and a reduction potentially of side effects and toxicities. So this analysis was a comparison because the TRANSCEND CLL 004 trial has two cohorts—actually it had three cohorts—but two major cohorts, liso-cel monotherapy and liso-cel plus ibrutinib. And this was an analysis. And overall, the conclusion was that there were improved responses, both complete response rate and overall response rate, for patients who received the combination of liso-cel plus ibrutinib versus patients who received liso-cel monotherapy. Progression-free survival, duration of response, overall survival were similar; side effect and toxicity profile were similar. But clearly there was, based on this propensity score analysis, an improved response rate associated with combination therapy versus liso-cel monotherapy.
Related Videos
The ASCO Post Staff
Karen Eubanks Jackson, Founder and Chief Executive Officer of Sisters Network Inc. and recipient of the 2025 ASCO Patient Advocate Award, discusses her 30-year-long effort to support patients with breast cancer in the Black community. Sisters Network is focused on raising awareness of early screening for breast cancer, providing financial assistance, and addressing the disparities Black women face in breast cancer care and outcomes.
The ASCO Post Staff
Raffaele Califano, MD, of the Christie NHS Foundation Trust and the University of Manchester, discusses outcomes by osimertinib resistance mechanisms in MARIPOSA-2, a study that evaluated the efficacy of the bispecific antibody amivantamab-vmjw plus chemotherapy vs chemotherapy in patients with EGFR-mutant advanced NSCLC after disease progression on osimertinib (Abstract 8639).
The ASCO Post Staff
Mafalda Oliveira, MD, PhD, of Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, discusses findings on the incidence and management of hyperglycemia in a subset of patients with prediabetes and/or obesity included in the phase I trial of inavolisib alone and in combination with endocrine therapy with or without palbociclib for PIK3CA-mutated, hormone receptor–positive, HER2-negative locally advanced/metastatic breast cancer (Abstract 1004).
The ASCO Post Staff
Manmeet Singh Ahluwalia, MD, MBA, FASCO, of Miami Cancer Institute, Baptist Health South Florida, discusses the ongoing LIBERATE trial, which is evaluating safety and technical efficacy of transcranial MR-guided microbubble-enhanced transcranial focused ultrasound for increasing blood circulating tumor and cell-free DNA levels in adults with glioblastoma (Abstract TPS2094).
The ASCO Post Staff
Yelena Y. Janjigian, MD, of Memorial Sloan Kettering Cancer Center, presents event-free survival data from the phase III MATTERHORN trial of the PD-L1 inhibitor durvalumab plus FLOT (fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy) in patients with resectable gastric or gastroesophageal junction (GEJ) cancer (LBA5).